Characterization of the complexes of furosemide with 2-hydroxypropyl-β-cyclodextrin and sulfobutyl ether-7-β-cyclodextrin

European Journal of Pharmaceutical Sciences

Volumn 16, Issue 4-5, 2002, Pages 247-253

  Spamer, Elisma ^a   Müller, Douw G ^a   Wessels, Philippus L ^b   Venter, Johannes P ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

2 Hydroxypropyl cyclodextrin; Complexation; Furosemide; Sulfobutyl ether 7 cyclodextrin

Indexed keywords

CALORIMETRY; CHARACTERIZATION; COMPLEXATION; ETHERS; MIXTURES; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGOMERS; X RAY DIFFRACTION;

TORUS CAVITIES;

DRUG PRODUCTS;

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CYCLODEXTRIN; FURAN DERIVATIVE; FUROSEMIDE; HYDROXYL GROUP;

ARTICLE; COMPLEX FORMATION; DIFFERENTIAL SCANNING CALORIMETRY; FREEZE DRYING; MOLECULE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; TECHNIQUE; X RAY DIFFRACTION;

BETA-CYCLODEXTRINS; CALORIMETRY, DIFFERENTIAL SCANNING; CYCLODEXTRINS; DRUG COMPOUNDING; FREEZE DRYING; FUROSEMIDE; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; SOLUBILITY; X-RAY DIFFRACTION;

EID: 0036743333     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(02)00107-0     Document Type: Article

References (15)

1. Al-Obaid A.M., Al-Shammary F.J., Al-Rashood K.A.M., Mian M.S. Analytical profile of furosemide. Florey K. Analytical Profiles of Drug Substances. Vol. 18: 1989;153-193 Academic Press New York.
2. Ammar H.O., Ghorab M., El-Nabhas S.A., Emara L.H., Makram T.S. Inclusion complexation of furosemide in cyclodextrins. Pharmazie. 54:2 1999;142-144.
3. Bekers O., Uijtendaal E.V., Beijnen J.H., Bult A., Underberg W.J.M. Cyclodextrins in the pharmaceutical field. Drug Dev. Ind. Pharm. 17:1991;1503-1549.
4. Boles Ponto L.L., Schoenwald R.D. Furosemide (frusemide): a pharmacokinetic/pharmacodynamic review. Part I. Clin. Pharmacokinet. 18:1990;381-408.
5. Duchêne D., Wouessidjewe D. Physiochemical characteristics and pharmaceutical uses of cyclodextrin derivatives. Part II. Pharm. Technol. 14:1990;26-34.
6. Kata M., Kedvessy G. Increasing the solubility characteristics of pharmaca with cyclodextrins. Pharm. Ind. 49:1987;98-100.
7. Kingsford M., Eggers N.J., Soteros G., Maling T.J.B., Shirkey R.J. An in vitro correlation for the bioavailability of frusemide tablets. J. Pharm. Pharmacol. 36:1984;536-538.
8. Loftson T., Brewster M.E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 85:1996;1017-1025.
9. Loukas Y.L., Vraka V., Gregoriades G. Novel non-acidic formulations of halopiridol complexed with β-cyclodextrin derivatives. J. Pharm. Biomed. Anal. 16:1997;263-268.
10. McNamara P.J., Fosler T.S., Digenis G.A. Influence of tablet dissolution on furosemide bioavailability: a bioequivalence study. Pharm. Res. 4:2 1987;150-153.
11. Murray M.D., Haag K.M., Black P.K., Hall S.D., Brater D.C. Variable furosemide absorption and poor predictability of response in elderly patients. Pharmacotherapy. 17:1997;98-106.
12. Özdemir N., Ordu S. Improvement of dissolution properties of furosemide by complexation with β-cyclodextrin. Drug Dev. Ind. Pharm. 24:1 1998;19-25.
13. Pitha J., Milecki J., Fabs H., Pannell L., Uekama K. Hydroxypropyl-β-cyclodextrin: preparation and characterization; effects on solubility of drugs. Int. J. Pharm. 29:1986;73-82.
14. Rowbotham P.C., Stanford J.B., Sugden J.K. Some aspects of the photochemical degradation of frusemide. Pharm. Acta Helv. 51:1976;304-307.
15. Williams R.O., Mahaguna V., Sriwongjanya M. Characterization of an inclusion complex of cholesterol and hydroxypropyl-β-cyclodextrin. Eur. J. Pharm. Biopharm. 46:1998;355-360.